Inventiva (NASDAQ:IVA) Shares Gap Down – Here’s Why

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shares gapped down before the market opened on Wednesday . The stock had previously closed at $4.56, but opened at $4.27. Inventiva shares last traded at $4.5040, with a volume of 487,692 shares traded.

Analyst Ratings Changes

IVA has been the topic of several recent research reports. Wall Street Zen downgraded shares of Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research note on Tuesday, April 21st. Finally, Truist Financial assumed coverage on Inventiva in a report on Thursday, March 19th. They issued a “buy” rating and a $13.00 target price for the company. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Inventiva currently has an average rating of “Buy” and a consensus target price of $16.56.

Inventiva Trading Down 2.9%

The business’s fifty day simple moving average is $4.48 and its two-hundred day simple moving average is $5.32.

Hedge Funds Weigh In On Inventiva

Hedge funds have recently made changes to their positions in the company. Creative Planning purchased a new stake in shares of Inventiva in the 2nd quarter valued at about $32,000. Virtu Financial LLC purchased a new stake in Inventiva in the fourth quarter valued at approximately $60,000. XTX Topco Ltd acquired a new stake in shares of Inventiva in the fourth quarter valued at approximately $84,000. Cerity Partners LLC purchased a new position in shares of Inventiva during the fourth quarter worth approximately $93,000. Finally, NewEdge Advisors LLC acquired a new position in shares of Inventiva in the 3rd quarter valued at $116,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.